Stock Price

The Chinese commercial EV maker is battling a collapsed stock price and dwindling cash, forcing a drastic ADS ratio change to maintain its US listing.

NFT Ltd. just raised $2.55 million to fund its pivot into AI and robotics. But deep dilution and a massive cash burn reveal a microcap struggling to survive.

In a swift move, HomeTrust Bancshares completed its 5% stock buyback and immediately authorized another, signaling deep confidence in its regional strength.

Vishal Garg has successfully ousted five directors to regain control of Better Home & Finance. Now, with new VC backing, can he fix the struggling lender?

Ahead of its Q2 2027 earnings report, we examine how the mobility SaaS provider is balancing robust global expansion with high operating leverage.

Keurig Dr Pepper finalizes its acquisition of JDE Peet's, triggering a massive corporate split and reshaping the global coffee supply chain.

A Nasdaq deficiency notice puts ATA Creativity Global on the clock. Can the Chinese edtech firm survive its radical restructuring and avoid delisting?

As 20/20 BioLabs brings its needle-free, AI-powered cancer tests to the Maxim Growth Summit, the startup faces intense scrutiny over its financial runway.

A proposed $38.25 million class action settlement exposes the perils of pre-COVID fixed-price contracts, but CAE's insurance strategy limits the damage.

Principal Real Estate Income Fund declares a 12.17% yield, but beneath the payout lies a complex web of leverage, return of capital, and rising CMBS risk.

Invesque's 10-cent take-private deal reveals how private credit titans are quietly absorbing distressed public real estate amid shifting capital markets.

PolyPid has regained European rights to its promising infection-fighting drug. Now begins a high-stakes race to secure a partner before approval.

C1 Fund takes its mission of accessible venture capital to major investor conferences, riding the momentum of high-profile portfolio milestones and buybacks.

As legacy CCTV yields to cloud-native AI, Cloudastructure's multi-property expansion highlights a high-stakes race between SaaS growth and cash runway.

By swapping restrictive public bonds for a flexible insider-backed debt and equity package, Gentoo Media secures its future at the cost of heavy dilution.

Targeted protein degradation is breaking out of oncology. Monte Rosa’s latest Phase 1 readout tests if molecular glues can solve residual heart disease risk.

As Visible Gold Mines consolidates its Quebec gold assets, the addition of a seasoned exploration executive signals a pivot toward aggressive resource development.

Zhongchao's latest 1-for-2 reverse stock split highlights the grueling struggle of Chinese micro-cap healthcare VIEs battling Nasdaq delisting pressures.

A surprise $96 million all-cash bid for Marygold's USCF ETF franchise sparks a fierce corporate battle, highlighting the race for scale in asset management.

Bimergen Energy aims to erase a 50% equity overhang to woo institutional partners, but a pending $100M shelf filing reveals a deeper strategic paradox.